Literature DB >> 8567926

Nonisotopic hybridization assay for determination of relative amounts of genotypic human immunodeficiency virus type 1 zidovudine resistance.

P S Eastman1, E Boyer, L Mole, J Kolberg, M Urdea, M Holodniy.   

Abstract

A nonisotopic hybridization assay for human immunodeficiency virus genotypic zidovudine resistance determination is described. Biotinylated PCR product was hybridized with enzyme-labeled probes for wild-type or resistant mutant sequences and detected colorimetrically or chemiluminescently in a microplate format. Changes in mutant-to-wild-type ratios allow for the monitoring of longitudinal patient samples.

Entities:  

Mesh：

Substances：

Year:  1995        PMID： 8567926      PMCID： PMC228576          DOI： 10.1128/jcm.33.10.2777-2780.1995

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN： 0095-1137            Impact factor:   5.948


  15 in total

1.  Nucleotide sequence and expression of an AIDS-associated retrovirus (ARV-2).

Authors:  R Sanchez-Pescador; M D Power; P J Barr; K S Steimer; M M Stempien; S L Brown-Shimer; W W Gee; A Renard; A Randolph; J A Levy
Journal:  Science       Date:  1985-02-01       Impact factor: 47.728

Review 2.  Resistance of clinical isolates of human immunodeficiency virus to antiretroviral agents.

Authors:  D D Richman
Journal:  Antimicrob Agents Chemother       Date:  1993-06       Impact factor: 5.191

3.  Multiple mutations in HIV-1 reverse transcriptase confer high-level resistance to zidovudine (AZT).

Authors:  B A Larder; S D Kemp
Journal:  Science       Date:  1989-12-01       Impact factor: 47.728

4.  Zidovudine resistance predicted by direct detection of mutations in DNA from HIV-infected lymphocytes.

Authors:  B A Larder; P Kellam; S D Kemp
Journal:  AIDS       Date:  1991-02       Impact factor: 4.177

5.  Comparison of selective polymerase chain reaction primers and differential probe hybridization of polymerase chain reaction products for determination of relative amounts of codon 215 mutant and wild-type HIV-1 populations.

Authors:  P S Eastman; M Urdea; D Besemer; M Stempien; J Kolberg
Journal:  J Acquir Immune Defic Syndr Hum Retrovirol       Date:  1995-07-01

6.  A microtitre format point mutation assay: application to the detection of drug resistance in human immunodeficiency virus type-1 infected patients treated with zidovudine.

Authors:  S Kaye; C Loveday; R S Tedder
Journal:  J Med Virol       Date:  1992-08       Impact factor: 2.327

7.  HIV-1 biological phenotype and the development of zidovudine resistance in relation to disease progression in asymptomatic individuals during treatment.

Authors:  C A Boucher; J M Lange; F F Miedema; G J Weverling; M Koot; J W Mulder; J Goudsmit; P Kellam; B A Larder; M Tersmette
Journal:  AIDS       Date:  1992-11       Impact factor: 4.177

8.  Zidovudine resistance and HIV-1 disease progression during antiretroviral therapy. AIDS Clinical Trials Group Protocol 116B/117 Team and the Virology Committee Resistance Working Group.

Authors:  R T D'Aquila; V A Johnson; S L Welles; A J Japour; D R Kuritzkes; V DeGruttola; P S Reichelderfer; R W Coombs; C S Crumpacker; J O Kahn; D D Richman
Journal:  Ann Intern Med       Date:  1995-03-15       Impact factor: 25.391

9.  Pol gene quasispecies of human immunodeficiency virus: mutations associated with drug resistance in virus from patients undergoing no drug therapy.

Authors:  I Nájera; A Holguín; M E Quiñones-Mateu; M A Muñoz-Fernández; R Nájera; C López-Galíndez; E Domingo
Journal:  J Virol       Date:  1995-01       Impact factor: 5.103

10.  Zidovudine-resistant human immunodeficiency virus type 1 genomes detected in plasma distinct from viral genomes in peripheral blood mononuclear cells.

Authors:  M S Smith; K L Koerber; J S Pagano
Journal:  J Infect Dis       Date:  1993-02       Impact factor: 5.226
View more
  10 in total

1.  HIV-1 genotypic resistance patterns predict response to saquinavir-ritonavir therapy in patients in whom previous protease inhibitor therapy had failed.

Authors:  A R Zolopa; R W Shafer; A Warford; J G Montoya; P Hsu; D Katzenstein; T C Merigan; B Efron
Journal:  Ann Intern Med       Date:  1999-12-07       Impact factor: 25.391

2.  Genotypic changes in human immunodeficiency virus type 1 associated with loss of suppression of plasma viral RNA levels in subjects treated with ritonavir (Norvir) monotherapy.

Authors:  P S Eastman; J Mittler; R Kelso; C Gee; E Boyer; J Kolberg; M Urdea; J M Leonard; D W Norbeck; H Mo; M Markowitz
Journal:  J Virol       Date:  1998-06       Impact factor: 5.103

3.  Nevirapine-resistant human immunodeficiency virus: kinetics of replication and estimated prevalence in untreated patients.

Authors:  D V Havlir; S Eastman; A Gamst; D D Richman
Journal:  J Virol       Date:  1996-11       Impact factor: 5.103

4.  Interlaboratory comparison of sequence-specific PCR and ligase detection reaction to detect a human immunodeficiency virus type 1 drug resistance mutation. The AIDS Clinical Trials Group Virology Committee Drug Resistance Working Group.

Authors:  R W Shafer; M A Winters; D L Mayers; A J Japour; D R Kuritzkes; O S Weislow; F White; A Erice; K J Sannerud; A Iversen; F Pena; D Dimitrov; L M Frenkel; P S Reichelderfer
Journal:  J Clin Microbiol       Date:  1996-07       Impact factor: 5.948

5.  A novel phenotypic drug susceptibility assay for human immunodeficiency virus type 1.

Authors:  C J Petropoulos; N T Parkin; K L Limoli; Y S Lie; T Wrin; W Huang; H Tian; D Smith; G A Winslow; D J Capon; J M Whitcomb
Journal:  Antimicrob Agents Chemother       Date:  2000-04       Impact factor: 5.191

6.  Line probe assay for rapid detection of drug-selected mutations in the human immunodeficiency virus type 1 reverse transcriptase gene.

Authors:  L Stuyver; A Wyseur; A Rombout; J Louwagie; T Scarcez; C Verhofstede; D Rimland; R F Schinazi; R Rossau
Journal:  Antimicrob Agents Chemother       Date:  1997-02       Impact factor: 5.191

7.  Emergence of protease inhibitor resistance mutations in human immunodeficiency virus type 1 isolates from patients and rapid screening procedure for their detection.

Authors:  M B Vasudevachari; Y M Zhang; H Imamichi; T Imamichi; J Falloon; N P Salzman
Journal:  Antimicrob Agents Chemother       Date:  1996-11       Impact factor: 5.191

8.  Randomized, controlled phase I/II, trial of combination therapy with delavirdine (U-90152S) and conventional nucleosides in human immunodeficiency virus type 1-infected patients.

Authors:  R T Davey; D G Chaitt; G F Reed; W W Freimuth; B R Herpin; J A Metcalf; P S Eastman; J Falloon; J A Kovacs; M A Polis; R E Walker; H Masur; J Boyle; S Coleman; S R Cox; L Wathen; C L Daenzer; H C Lane
Journal:  Antimicrob Agents Chemother       Date:  1996-07       Impact factor: 5.191

9.  Line probe assay for detection of human immunodeficiency virus type 1 mutations conferring resistance to nucleoside inhibitors of reverse transcriptase: comparison with sequence analysis.

Authors:  D Descamps; V Calvez; G Collin; A Cécille; C Apetrei; F Damond; C Katlama; S Matheron; J M Huraux; F Brun-Vézinet
Journal:  J Clin Microbiol       Date:  1998-07       Impact factor: 5.948

10.  A multiple-site-specific heteroduplex tracking assay as a tool for the study of viral population dynamics.

Authors:  W Resch; N Parkin; E L Stuelke; T Watkins; R Swanstrom
Journal:  Proc Natl Acad Sci U S A       Date:  2001-01-02       Impact factor: 11.205
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.